Immediate test results and patient treatment reduces the likelihood of a readmission “within 30 days of discharge” that could result in hospital penalties under Accountable Care.
“Consolidates and replaces a suitcase full of readers with a single device, that adapts to existing and FDA Cleared Point of Care tests, eliminates transportation of patient samples to central labs by testing the patient wherever they are, and transmits test results directly to The Cloud. The device that finally makes Point of Care diagnostics practical for healthcare providers."
Murrieta / San Diego— 11/10/2020 — Today GattaCo and iAssay announced that they have signed a Memorandum of Understanding (MOU), enabling engineers and scientists to work together to integrate and optimize their products in an effort to provide enhanced rapid serology testing, including COVID-19 antibody testing and electronic test result transmission to federal and state […]
We are excited to share the stage with so many top talents in the innovation space. The patented iAssay® System is a handheld medical test reader. It is agnostic to test type, and features an expandable test menu for testing patients at point of care using a fingerstick blood sample or urine sample. Flexibility by […]
iAssay automatically sends COVID-19 test results to the Cloud! This has always been a part of the plan because of its anticipated importance. Now that HHS has mandated that COVID-19 test results be sent to them periodically, iAssay will have you covered! Comply with us! Courtesy of Patricia Jones, PhD and The AACC On September […]
The USPTO granted iAssay US Patent 10,753,921 on August 25, 2020. This is the Continuation in Part (CIP) of US Patent 10,309,954 granted in June, 2019. Another exciting CIP application was filed the day before the latest patent granted on August 24, 2020.
San Diego – Sept 1, 2020 Dr. Edward Strong, the geneticist who co-founded and served as CEO of MedGenomics, Inc., has been named Scientific Director of iAssay, Inc. Strong will guide the researchers and engineers who are developing iAssay’s product line. iAssay is creating a suite of tools that support remote testing for COVID-19 and other […]
iAssay would like to meet with both investors in the point of care diagnostics space AND those with point of care strips, cartridges, labs on a chip looking for a Cloud connected reader. If you plan to attend, our calendar on RESI is up-to-date. Just request a meeting while slots are open. When we run […]
San Diego, California–May 28, 2020 — iAssay® Inc., a privately held developer of the world’s first open platform reader for Point of Care, Cloud Connected remote diagnostics, today announced that is has been honored by CONNECT W/San Diego Venture Group to be selected as a 2020 COOL COMPANY. “We received a record number of applications […]
iAssay is working on putting together a Point of Care testing solution for COVID-19. This includes automatically recording test results in The Cloud supporting patient records and also epidemiological studies. The iAssay system concept lends itself to simply onboarding new testing needs as they arise. Please stay tuned to our website for late breaking updates […]
It’s that time again! Time for the JP Morgan Healthcare meeting. The iAssay team will be at the 38th Annual JP Morgan Healthcare Conference from January 13 to January 15, 2020. We would love to catch up with you. For more information on the meeting, check out https://www.jpmorgan.com/global/healthcareconference . We are interested in talking […]